title: The role of the insulin-like growth factor 1 receptor axis in multiple myeloma.
abstract: Multiple myeloma remains a fatal B cell malignancy with severe clinical features such as anaemia and bone fractures, caused by the predominant localization of the myeloma cells in the bone marrow (BM). The MM cells first migrate towards the BM, followed by their clonal expansion and induction of angiogenesis and osteolysis. Insulin-like growth factor 1 or IGF-1 is a cytokine which plays a role in myeloma development. Besides serving as a growth and survival factor, it attracts the cells towards the BM, and is involved in the angiogenesis process. This makes the IGF-1R an interesting target for therapeutical interventions. Apart from mediating aspects of the malignant phenotype, it also appears not to be an absolute requirement for normal cell homeostasis. Various strategies targeting the IGF-1R have emerged with the two main strategies being blocking antibodies and small molecule inhibitors. After encouraging preclinical results both strategies are now in clinical trials.
authors.affiliation: Myeloma Research Centre, Brussels, Department of Hematology and Immunology, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium. emenu@vub.ac.be
authors.forename: Eline
authors.initials: E
authors.lastname: Menu
authors.forename: Els
authors.initials: E
authors.lastname: van Valckenborgh
authors.forename: Ben
authors.initials: B
authors.lastname: van Camp
authors.forename: Karin
authors.initials: K
authors.lastname: Vanderkerken
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D017526:Receptor, IGF Type 1